Viridian Therapeutics announced that enrollment is complete in THRIVE-2, its phase 3 clinical trial for VRDN-001 in patients with chronic TED.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Wedbush reveals three potential buyout targets for Biogen
- Viridian Therapeutics Releases Updated Investor Presentation
- Viridian Therapeutics’ Shareholders Approve Equity Plan Expansion
- Viridian Therapeutics updates VRDN-003 Phase 3 program in thyroid eye disease
- Viridian Therapeutics initiated with an Outperform at Wolfe Research
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue